soul trial oral semaglutide cardiovascular outcomes results 2024 nejm (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Cardiovascular risk reduction with once-weekly

As part of the approval process, it underwent rigorous safety testing and was deemed safe and effective

The role of the vagus nerve in appetite control: implications for the pathogenesis of obesity

This deficiency can occur as a primary one due to genetic disorder that disrupts carnitine transport, or as a secondary one coming from problems such as malnutrition, certain medical conditions, or the intake of particular medications

Consistent with previous reports, Hey1-eGFP expression is also detected in some epithelial cells and DLL4 + ECs 39,40,41,42

3fh) and was able to lessen the glucose-lowering effect of linagliptin in both PDX1Cre control and Gcg RA PDX1Cre mice